[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers

Inclusion Criteria

• •Age ≥18 years old.
• •2\. Adequate organ function (obtained within 14 days prior to PET scan \[Part 1, Part 2, and Part 3 ONLY\] or within 28 days prior to PET scan \[Part 4 ONLY\]) as evidenced by:
• •1. ANC ≥ 1.5 X 10\^9/L w/o myeloid growth factor support for 7 d preceding lab assessment
• •2. Hgb ≥ 9 g/dL (90 g/L); \< 9 g/dL (\< 90 g/L) is acceptable if Hgb is corrected to ≥ 9 g/dL (90 g/L) as by growth factor or transfusion prior to PET scan
• •3. Platelet count ≥ 100 X 10\^9/L w/o blood transfusions for 7 d preceding lab assessment
• •4. Bilirubin ≤ 1.5 X ULN except for pts w/ documented history of Gilbert's disease
• •5. ALT and AST ≤ 2.5 X ULN
• •6. Alkaline phosphatase (AP) ≤ 3 X ULN
• •7. Women of childbearing potential (WCBP): negative serum pregnancy test
• •3\. Ability to stand up and climb two steps with minimal assistance.
• •4\. Ability to understand and the willingness to sign a written informed consent document.
• •5\. (Part 2, intracranial tumor patients ONLY) (a) Radiographical or pathological evidence of newly-diagnosed intracranial tumor that is status-pre surgical resection, or (b) Radiographical or pathological evidence of progressive/recurrent intracranial tumor, (c) Question of pseudoprogression vs. true progression on most recent standard-of-care brain MRI, or (d) Evidence on the most recent standard-of-care brain MRI scan of intracranial metastasis/metastases in a patient with known extracranial primary cancer.
• •6\. (Part 3, GBM patients ONLY) Any patient with at least a 1cm3 contrast-enhancing lesion suspicious for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM, molecular GBM, diffuse astrocytomas with molecular features of GBM, H3K27M midline gliomas, gliosarcomas, or any other WHO Grade IV glioma) on a standard-of-care (SOC) brain MRI scan. If the patient undergoes a biopsy or resection for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM, molecular GBM, diffuse astrocytomas with molecular features of GBM, H3K27M midline gliomas, gliosarcomas, or any other WHO Grade IV glioma) then the remaining contrast-enhancing lesion is at least 1cm3 in size on the post-operative scan.
• •7\. (Part 3, GBM patients ONLY) Life expectancy of ≥ 6 months.